Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.58 |
| ▸ | PREP | P48147 | 3/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL809494 | 1.00 | SPHK2 (0.58) | SPHK2PREPACE2SMN1; SMN2NPC1 | |
| SCHEMBL5267939 | 1.00 | SPHK2 (0.58) | SPHK2PREPACE2SMN1; SMN2NPC1 | |
| SCHEMBL1190565 | 0.96 | SPHK2 (0.54) | SPHK2PREPACE2SMN1; SMN2NPC1 | |
| SCHEMBL80752 | 0.96 | SPHK2 (0.54) | SPHK2PREPACE2SMN1; SMN2NPC1 | |
| SCHEMBL3605585 | 0.96 | SPHK2 (0.54) | SPHK2PREPACE2SMN1; SMN2NPC1 | |
| SCHEMBL7561453 | 0.95 | SPHK2 (0.53) | SPHK2PREPACE2SMN1; SMN2NPC1 | |
| SCHEMBL6252758 | 0.92 | SMN1; SMN2 (0.56) | PREPSMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL4186350 | 0.92 | SMN1; SMN2 (0.56) | PREPSMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL4186357 | 0.92 | SMN1; SMN2 (0.56) | PREPSMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL10749955 | 0.90 | PREP (0.67) | SPHK2PREPCTRB1NPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118355020-A | Therapeutic compounds for HIV virus infection | 吉利德科学公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-113603683-B | Substituted phenyl oxazolidinones for antimicrobial treatment | 结核病药物开发全球联盟公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4219718-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-113603683-A | Substituted phenyl oxazolidinones for antimicrobial therapy | 结核病药物开发全球联盟公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-108348507-B | Substituted phenyl oxazolidinones for antimicrobial therapy | 结核病药物开发全球联盟公司 | 2021-10-08 | — | — | CN | disclosed |
| EP-3862362-A2 | CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3828275-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3757215-A2 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3137091-B1 | CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3690049-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| US-5569768-A | USEFUL IN TREATING HYPERTENSION, CONGESTIVE HEART FAILURE, GLAUCOMA AND RENAL INSUFFICIENCY | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5556981-A | Angiotensin II antagonist intermediates | ELI LILLY AND COMPANY (US) | 1996-09-17 | — | — | US | disclosed |
| CN-1101908-A | Angiotensin II antagonists | LILLY CO ELI (US) | 1995-04-26 | — | — | CN | disclosed |
| EP-0574174-A2 | Angiotensin II antagonists | ELI LILLY AND COMPANY (US) | 1993-12-15 | — | — | EP | disclosed |
| EP-0309624-B1 | COMPOSITION FOR ENHANCING PERCUTANEOUS ADMINISTRATION OF MEDICINE | NITTO DENKO CORPORATION (JP) | 1992-03-11 | — | — | EP | disclosed |
| US-5059628-A | Proline or prolinol ester to enhance absorption | NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1991-10-22 | — | — | US | disclosed |
| WO-1989012633-A1 | BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | E.R. SQUIBB & SONS, INC. (US) | 1989-12-28 | — | — | WO | disclosed |
| US-4835164-A | HYPOTENSIVE AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-05-30 | — | — | US | disclosed |
| EP-0309624-A1 | Composition for enhancing percutaneous administration of medicine | NITTO DENKO CORPORATION (JP) | 1989-04-05 | — | — | EP | disclosed |
| EP-0279707-A2 | Aryloxymethyl derivatives of nitrogenous heterocyclic methanols and ethers thereof having cardiovascular activity | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-08-24 | — | — | EP | disclosed |